🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Identification of High-Risk Imaging Features in Hypertrophic Cardiomyopathy using Electrocardiography: A Deep-Learning Approach @rtcarrick heartrhythmjournal.com/article/S1547-…

Great work but Richard Carrick creating this model in collaboration with Kathy Wu and Hisham Ahamed MD DM. ECG using deep learning identifies patients who need a cardiac MRI to ID high risk features.

Maintenance of SICD in young patients with obstructive HCM who have undergone myectomy is advised given low rates of complications related to T‐wave oversensing & long‐term benefits of avoiding transvenous systems. #AHAJournals #ResearchLetter Ethan Rowin ahajournals.org/doi/10.1161/JA…

Great work by Amro Aglan Ayman Fath, MD and team evaluating if LAA closure is effective to prevent strokes in HCM patients with AF

Novel data underscore an essential principle in HCM: genetic testing results do not reliably predict prognosis or dictate management decisions for individual patients. #AHAJournals Jiří Bonaventura Ethan Rowin Michael Chin, MD, PhD Martin Maron, MD ahajrnls.org/3XoCSzt

📯LGE=0 was associated with very low rates of SCD (0.34%/y) and mortality among #HCM. Zero LGE had a strong negative predictive value over 5 yrs from initial #CMR. When do we rescan again⁉️ Glad to share our 📜 JACC Journals led by Matthew W Martinez Martin Maron, MD Ethan Rowin

Percutaneous Left Atrial Appendage Closure for Stroke Prevention in Hypertrophic Cardiomyopathy Patients with Atrial Fibrillation Ethan Rowin heartrhythmjournal.com/article/S1547-…

🚨 Boston is SOLD OUT!🎟️ Get your VIRTUAL ticket for #HCMSummit8 & join us live Oct 25-27 to learn from leading global #HCM experts, with on-demand access thru April 2025. Don’t miss out! Tickets: hcmsummit.org/tickets #CardioResearch #HypertrophicCardiomyopathy #CardioTwitter

Our third Industry Product Theater is sponsored by iRhythm Technologies & all attendees are invited! Sat, Oct 26 @ 7:15 AM ET w Matthew W Martinez Anjali Owens Ethan Rowin #dannaspears & #barrymaron. Details: hcmsummit.org/irhythm #HCMSummit8 #HCM #CardioTwitter #HypertrophicCardiomyopathy

Extended Ambulatory ECG Monitoring Enhances Identification of Higher-Risk Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy heartrhythmjournal.com/article/S1547-…

Rick Nishimura and Dr. Barry Maron at #HCMSummit8. Great to hear from many experts on HCM. The International HCM Summit Steve Ommen, MD Martin Maron, MD

#cardiotwitter: How do you approach apical aneurysms in hypertrophic #cardiomyopathy? Excited to contribute to the latest Hypertrophic Cardiomyopathy Medical Society "In the Thick of It" podcast with Ethan Rowin #cvHCM pod.link/1694758840/epi…

Disopyramide for long-term treatment of obstructive #hcm? Check out our work looking at patients treated for ≥5 years at NYU Langone Health Lahey Hospital with 67% still on drug after ~7 years Ethan Rowin Martin Maron, MD ahajournals.org/doi/full/10.11…

Disopyramide appears safe and effective in treating symptomatic outflow obstruction in HCM over extended durations of time (≥5 years). #AHAJournals Daniele Massera NYU Langone Health Ethan Rowin Lahey Hospital ahajrnls.org/4hC5AnC

Mavacamten in #nonobstructive #HCM design and baseline characteristics paper is out (ODYSSEY trial) ! Biggest unmet need in HCM is nonobstructive HCM. We look forward to the results. Impressive baseline characteristics with significant burden of disease Sample size caught

“Excited to share our latest editorial published in Circulation - Our study highlights T1 mapping as a novel marker for heart failure progression in hypertrophic cardiomyopathy (HCM). Ethan Rowin JAHA AHA Science

Really valuable and novel data presented by Dr. Ethan Rowin — Does LV apical aneurysm size matter for SCD risk in #HCM? 🏥 Multicenter data says yes! #ACC25 #CardioTwitter

How have HCM mortality rates changed before and after COVID ❓ 1⃣ Prior to COVID, mortality rates declined by ~ half📉 2⃣ After COVID, mortality rates increased by ~30%, partially undoing some of the prior reductions in HCM mortality.📈 Open access📜: ahajournals.org/doi/full/10.11…

New mavacamten FDA label update Most relevant parts: 1) Initiation strategy remains the same 2) Maintenance phase echo requirement dropped to once every 6 months instead of once every 3 months This will help with patient and staff burden during the maintenance phase. I would

Amazing session on #HCM and arrhythmias — from the newer high-risk makers to challenges of VT ablation, role of PFA, and updated exercise guidelines. #EPeeps #HRS2025 #2025pacesetter Ethan Rowin